Stifel has revised its price target for Inspire Medical Systems (INSP, Financial), lowering it from $190 to $175 while maintaining a Hold rating on the stock. The adjustment reflects evolving market conditions that have made Inspire's valuation more appealing. Nonetheless, Stifel has expressed concerns regarding potential challenges the company might encounter, suggesting that forthcoming news could impact the stock's performance in the near term.
Despite the current attractiveness of Inspire's valuation and its strong position to handle potential tariff changes, the firm anticipates volatility for Inspire Medical shares over the upcoming six months. Investors are advised to be mindful of this outlook as it may influence the company's stock trajectory during this period.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 15 analysts, the average target price for Inspire Medical Systems Inc (INSP, Financial) is $229.87 with a high estimate of $280.00 and a low estimate of $175.00. The average target implies an upside of 53.03% from the current price of $150.21. More detailed estimate data can be found on the Inspire Medical Systems Inc (INSP) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, Inspire Medical Systems Inc's (INSP, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Inspire Medical Systems Inc (INSP, Financial) in one year is $432.50, suggesting a upside of 187.93% from the current price of $150.21. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Inspire Medical Systems Inc (INSP) Summary page.
